Search

Your search keyword '"Coakley, Brian A."' showing total 165 results
Start Over Author "Coakley, Brian A."
165 results on '"Coakley, Brian A."'

15. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.

Author

Chen, Hui-Ming, Ma, Ge, Gildener-Leapman, Neil, Eisenstein, Samuel, Coakley, Brian, Ozao, Junko, Mandeli, John, Divino, Celia, Schwartz, Myron, Sung, Max, Ferris, Robert, Kao, Johnny, Wang, Lu-Hai, Pan, Ping-Ying, Ko, Eric, and Chen, Shu-Hsia

Subjects
Antineoplastic Agents, CD11b Antigen, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cell Proliferation, Cell Survival, Disease Progression, Flow Cytometry, Humans, Immune System, Immunosuppressive Agents, Indoles, Leukocytes, Mononuclear, Monocytes, Myeloid Cells, Neoplasm Metastasis, Neoplasms, Phosphorylation, Pyrroles, Radiosurgery, STAT3 Transcription Factor, Sialic Acid Binding Ig-like Lectin 3, Sunitinib, Treatment Outcome
Abstract

PURPOSE: The clinical effects of sunitinib on human myeloid-derived suppressor cell (MDSC) subsets and correlation of the T-cell-mediated immune responses and clinical outcomes in patients with oligometastases treated by stereotactic body radiotherapy (SBRT) have been evaluated. EXPERIMENTAL DESIGN: The numbers of granulocytic and monocytic MDSC subsets, effector T cells, and regulatory T cells in the peripheral blood were evaluated pre- and post-sunitinib treatment and concurrent with SBRT. Correlations between MDSC, Treg, and T-cell responses and clinical outcomes were analyzed. RESULTS: Patients with oligometastases of various cancer types had elevated granulocytic MDSC and certain subsets of monocytic MDSC population. Sunitinib treatment resulted in a significant reduction in monocytic MDSC, phosphorylated STAT3, and arginase levels in monocytic MDSC (CD33(+)CD14(+)CD16(+)), and an increase in T-cell proliferative activity in cancer patients. Interestingly, the effects of sunitinib on reducing the accumulation and immune-suppressive function of MDSC were significantly correlated with Treg reduction, in responders but not in nonresponding patients. SBRT synergized the therapeutic effects of sunitinib, especially as related to decreased numbers of monocytic MDSC, Treg, and B cells, and augmented Tbet expression in primary CD4 and CD8 T cells. These effects were not observed in patients receiving radiation therapy alone. Most interestingly, the responders, defined by sunitinib-mediated reduction in CD33(+)CD11b(+) myeloid cell populations, tend to exhibit improved progression-free survival and cause-specific survival. CONCLUSIONS: Sunitinib treatment increased the efficacy of SBRT in patients with oligometastases by reversing MDSC and Treg-mediated immune suppression and may enhance cancer immune therapy to prevent tumor recurrence post-SBRT.

Published
2015

18. Supplementary Figure Legend from Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy

Author

Chen, Hui-Ming, primary, Ma, Ge, primary, Gildener-Leapman, Neil, primary, Eisenstein, Samuel, primary, Coakley, Brian A., primary, Ozao, Junko, primary, Mandeli, John, primary, Divino, Celia, primary, Schwartz, Myron, primary, Sung, Max, primary, Ferris, Robert, primary, Kao, Johnny, primary, Wang, Lu-Hai, primary, Pan, Ping-Ying, primary, Ko, Eric C., primary, and Chen, Shu-Hsia, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 1, Figures 1-5 from Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy

Author

Chen, Hui-Ming, primary, Ma, Ge, primary, Gildener-Leapman, Neil, primary, Eisenstein, Samuel, primary, Coakley, Brian A., primary, Ozao, Junko, primary, Mandeli, John, primary, Divino, Celia, primary, Schwartz, Myron, primary, Sung, Max, primary, Ferris, Robert, primary, Kao, Johnny, primary, Wang, Lu-Hai, primary, Pan, Ping-Ying, primary, Ko, Eric C., primary, and Chen, Shu-Hsia, primary

Published
2023
Full Text
View/download PDF

47. Predictors of Mortality Among Very Low Birth Weight Infants With Gastrointestinal Perforation

Author

Reppucci, Marina L., Hersh, Eliza H., Khetan, Prerna, and Coakley, Brian A.

Abstract

Background Gastrointestinal (GI) perforation is a risk factor for mortality in very low birth weight (VLBW) infants. Little data exist regarding pretreatment factors and patient characteristics known to independently correlate with risk of death.Materials and Methods A retrospective review of all VLBW infants who sustained GI perforation between 2011 and 2018 was conducted. Birth, laboratory, and disease-related factors of infants who died were compared to those who survived.Results 42 VLBW infants who sustained GI perforations were identified. Eleven (26.19%) died. There were no significant differences in birth-related factors, hematological lab levels at diagnosis, presence of pneumatosis, or bacteremia. Portal venous gas (P= .03), severe metabolic acidosis (P< .01), and elevated lactate at diagnosis (P< .01) were statistically more likely to occur among infants who died.Discussion Portal venous gas, severe metabolic acidosis, and elevated lactate were associated with an increased risk of mortality among VLBW infants who develop a GI perforation. Further research is required to better identify risk factors.

Published
2021
Full Text
View/download PDF

49. Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases.

Author

Reiter, Audra J, Huang, Lynn, Craig, Brian T, Talbot, Lindsay J, Aldrink, Jennifer H, Polites, Stephanie F., Dasgupta, Roshni, Malek, Marcus M., Piche, Nelson, Lovvorn, Harold N, Petroze, Robin, Le, Hau D, Rich, Barrie S., Seemann, Natashia M, Roach, Jonathan, Kastenberg, Zachary J, Coakley, Brian A, Grant, Christa N, Tracy, Elisabeth T, and Lautz, Timothy

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results